Böblingen, February 20, 2025 – The family-owned company Wörwag Pharma achieved an organic revenue growth of 10.5% in 2024, significantly outperforming the market across all 35 countries where it operates. The company generated a revenue of €331 million with around 1,500 dedicated employees worldwide.
Wörwag Pharma: Dynamic Growth and Expanded Market Presence
from left: Chief Executive Officer Jochen Schlindwein and Chief Financial Officer Gerhard Mayer
From a quaint city pharmacy, Wörwag Pharma has evolved into a global pharmaceutical player. In 2024, the company, with its approximately 1,500 globally active and dedicated employees, achieved a revenue of 331 million euros, significantly outperforming the general market development in some areas. This success reflects not only the company's resilience but also a portfolio of strong brands appreciated by both doctors and patients, supported by an inspiring corporate culture. Innovation, constructive collaboration, and a deep commitment to patient health are the cornerstones of the company's sustainable growth over the past years.
Wörwag Pharma Increases Production Volume
In 2023, the Wörwag Pharma Production site in Pöcking, Bavaria, was acquired. "Since the acquisition, we have continuously increased production volume through the successful establishment of our products," said Chief Financial Officer Gerhard Mayer. "In 2025, 42% of the Wörwag Pharma packages sold and 33% of the product portfolio will come from our two production sites in Poland and Pöcking," Mayer added.
Wörwag Pharma Records Significant Revenue Growth in the Asia Region
Wörwag Pharma has recorded impressive revenue growth in the Asia region (Vietnam, Thailand, and the Philippines). In 2024, revenue reached a remarkable 8.3 million euros, representing a significant increase of 72% compared to the previous year. This positive development underscores the successful implementation of the company's growth strategy in this dynamic region. Further revenue growth is also forecasted for 2025, highlighting Wörwag Pharma's continuous growth potential in Asia. Alongside this revenue growth, the number of employees in the region has also developed positively, more than doubling since 2019.
Expanded Portfolio
The dietary supplement ReDia® with a patented formula was acquired by Wörwag Pharma GmbH & Co. KG in 2024 and will be produced in-house in the future. "We are pleased to be able to incorporate and further develop this product into our portfolio," said Chief Executive Officer Jochen Schlindwein. The product launch is planned for several countries in 2025, including Germany. ReDia® is an innovative, fiber-rich dietary supplement. Taken before a meal, it helps to reduce the rise in blood sugar levels. Wörwag Pharma has specialized in biofactor products for over 50 years and has gained worldwide expertise in this area. "ReDia® perfectly complements our portfolio as it meets the growing consumer need for blood sugar regulation," Schlindwein added.